McKesson (MCK) Expected to Announce Quarterly Earnings on Wednesday

McKesson (NYSE:MCK) is anticipated to release its Q3 2026 results after the market closes on Wednesday, February 4th. Analysts expect McKesson to post earnings of $9.19 per share and revenue of $105.9821 billion for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earning report page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 4:30 PM ET.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $9.86 EPS for the quarter, beating analysts’ consensus estimates of $8.84 by $1.02. The company had revenue of $103.15 billion for the quarter, compared to analyst estimates of $103.80 billion. McKesson had a negative return on equity of 248.14% and a net margin of 1.04%.The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company posted $7.07 earnings per share. On average, analysts expect McKesson to post $33 EPS for the current fiscal year and $37 EPS for the next fiscal year.

McKesson Stock Performance

NYSE:MCK opened at $835.21 on Wednesday. The stock has a 50-day simple moving average of $829.92 and a 200 day simple moving average of $772.05. McKesson has a 52-week low of $570.51 and a 52-week high of $895.58. The company has a market cap of $103.09 billion, a PE ratio of 25.99, a PEG ratio of 1.36 and a beta of 0.41.

McKesson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 2nd. Stockholders of record on Monday, December 1st were paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend was Monday, December 1st. McKesson’s dividend payout ratio (DPR) is currently 10.21%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on MCK shares. Jefferies Financial Group boosted their price objective on shares of McKesson from $820.00 to $900.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. TD Cowen restated a “buy” rating on shares of McKesson in a research note on Monday, December 22nd. Wells Fargo & Company lifted their target price on McKesson from $816.00 to $914.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. UBS Group upped their target price on McKesson from $920.00 to $980.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Finally, Morgan Stanley raised their price target on McKesson from $857.00 to $916.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $895.79.

Insider Activity at McKesson

In other news, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $861.63, for a total value of $283,476.27. Following the completion of the sale, the chief accounting officer directly owned 328 shares of the company’s stock, valued at $282,614.64. This trade represents a 50.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Thomas L. Rodgers sold 276 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the transaction, the executive vice president directly owned 2,268 shares in the company, valued at $1,851,096.24. The trade was a 10.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.08% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On McKesson

Several large investors have recently modified their holdings of the stock. SurgoCap Partners LP boosted its holdings in shares of McKesson by 68.7% during the 3rd quarter. SurgoCap Partners LP now owns 452,261 shares of the company’s stock worth $349,390,000 after buying an additional 184,106 shares during the period. Wellington Management Group LLP lifted its position in McKesson by 32.9% during the third quarter. Wellington Management Group LLP now owns 618,984 shares of the company’s stock worth $478,190,000 after acquiring an additional 153,182 shares during the last quarter. Canada Pension Plan Investment Board boosted its holdings in shares of McKesson by 443.0% during the second quarter. Canada Pension Plan Investment Board now owns 105,613 shares of the company’s stock worth $77,391,000 after acquiring an additional 86,162 shares during the period. Boston Partners grew its position in shares of McKesson by 6.7% in the third quarter. Boston Partners now owns 1,330,953 shares of the company’s stock valued at $1,027,569,000 after purchasing an additional 83,357 shares during the last quarter. Finally, Man Group plc increased its stake in shares of McKesson by 40.1% during the second quarter. Man Group plc now owns 239,324 shares of the company’s stock worth $175,372,000 after purchasing an additional 68,454 shares during the period. 85.07% of the stock is owned by institutional investors.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.